Incyte Corporation (INCY) Return on Invested Capital (ROIC): 20.58%
Is Incyte Corporation’s return on invested capital (ROIC) high or low?
Incyte Corporation's return on invested capital (ROIC) of 20.58% is 189% above its 5-year average of 7.13%, near the high end of its 5-year range (-8.95%–20.58%).
As of Sunday, June 21, 2026. 97.41% above its 12-month average of 10.42%.
INCY Return on Invested Capital (ROIC) Chart
INCY Average Return on Invested Capital (ROIC) Chart
INCY Current vs Average Return on Invested Capital (ROIC) Chart
INCY Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
20.58%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
10.42%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
9.36%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
7.13%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
5.80%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
4.29%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
0.56%
CURRENT VS TTM AVG
+97.41%
CURRENT VS 3Y AVG
+119.99%
CURRENT VS 5Y AVG
+188.64%
CURRENT VS 10Y AVG
+255.05%
CURRENT VS 15Y AVG
+380.17%
CURRENT VS 20Y AVG
+3575.00%
INCY Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $19.62B | 20.58% | 10.42% | 9.36% | 7.13% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 7.39% | 6.30% | 5.64% | 7.56% |
| Viatris Inc. (VTRS)vs › | $17.90B | -7.95% | -3.96% | -1.19% | -0.87% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 5.48% | 5.58% | 5.01% | 3.94% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 7.35% | 8.59% | 9.78% | 13.56% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 16.14% | 15.79% | 14.57% | 13.09% |
| BioNTech SE (BNTX)vs › | $22.98B | -3.14% | -4.79% | 9.55% | 20.42% |
| Mettler-Toledo International Inc. (MTD)vs › | $23.13B | 35.46% | 38.26% | 37.51% | 36.01% |
| Waters Corporation (WAT)vs › | $23.17B | 17.57% | 18.00% | 20.73% | 22.79% |
| Veeva Systems Inc. (VEEV)vs › | $24.90B | 9.48% | 9.25% | 9.54% | 11.31% |
Capital Efficiency
ROIC
20.6%
ROE
25.8%
Incyte Corporation Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Incyte Corporation Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Incyte Corporation (INCY)?
- The return on invested capital (ROIC) for INCY stock is 20.58%.
- Is Incyte Corporation's return on invested capital (ROIC) high or low?
- Incyte Corporation's return on invested capital (ROIC) of 20.58% is 189% above its 5-year average of 7.13%, near the high end of its 5-year range (-8.95%–20.58%).
- What is the TTM average return on invested capital (ROIC) for Incyte Corporation (INCY)?
- The TTM average return on invested capital (ROIC) for INCY stock is 10.42%.
- What is the 3Y average return on invested capital (ROIC) for Incyte Corporation (INCY)?
- The 3Y average return on invested capital (ROIC) for INCY stock is 9.36%.
- What is the 5Y average return on invested capital (ROIC) for Incyte Corporation (INCY)?
- The 5Y average return on invested capital (ROIC) for INCY stock is 7.13%.
- What is the 10Y average return on invested capital (ROIC) for Incyte Corporation (INCY)?
- The 10Y average return on invested capital (ROIC) for INCY stock is 5.80%.
- What is the 15Y average return on invested capital (ROIC) for Incyte Corporation (INCY)?
- The 15Y average return on invested capital (ROIC) for INCY stock is 4.29%.
- What is the 20Y average return on invested capital (ROIC) for Incyte Corporation (INCY)?
- The 20Y average return on invested capital (ROIC) for INCY stock is 0.56%.
Incyte Corporation Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 20.58% |
| 2024-12-31 | 0.27% |
| 2023-12-31 | 8.46% |
| 2022-12-31 | 8.11% |
| 2021-12-31 | 14.31% |
| 2020-12-31 | -8.95% |
| 2019-12-31 | 12.55% |
| 2018-12-31 | 5.48% |
| 2017-12-31 | -12.58% |
| 2016-12-31 | 10.31% |
| 2015-12-31 | 5.22% |
| 2014-12-31 | -0.71% |
| 2013-12-31 | -3.09% |
| 2012-12-31 | 0.59% |
| 2011-12-31 | 136.57% |
| 2010-12-31 | 3.74% |
| 2009-12-31 | 0.00% |
| 2008-12-31 | -87.50% |
| 2007-12-31 | -35.67% |
| 2006-12-31 | -25.26% |
| 2005-12-31 | -28.95% |
| 2004-12-31 | -30.66% |
| 2003-12-31 | -44.25% |
| 2002-12-31 | -27.95% |
| 2001-12-31 | -10.44% |
| 2000-12-31 | -7.72% |
| 1999-12-31 | -15.39% |
| 1998-12-31 | 4.01% |
| 1997-12-31 | 2.29% |
| 1996-12-31 | 0.00% |
Related Metrics
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury